European Psychiatry S243

### **EPP0350**

# Assessment of Self-Esteem Among Tunisian Cannabis Users

S. Brahim $^{1*}$ , M. Henia $^{2}$ , A. Haj Mohamed $^{1}$ , M.H. Aoun $^{2}$  and L. Zarrouk $^{2}$ 

<sup>1</sup>University Hospital of Mahdia, Psychiatry, chebba, Tunisia and

<sup>2</sup>University Hospital of Mahdia, Tunisia., Psychiatry, mahdia, Tunisia \*Corresponding author.

doi: 10.1192/j.eurpsy.2022.626

**Introduction:** Cannabis is among the most widely used substances in the world. it is associated with several mental health problems. **Objectives:** To assess self-esteem among a group of young Tunisian users of cannabis.

**Methods:** The total study sample was composed of 137 participants, who took part of a transversal descriptive study during two months (January and February 2020).

Results: In our study population, the cannabis consumers were young adults aged between 18 and 35 years old, with a male predominance of 71%. Among those users, 65.9% were single and 29.7% dropped out of school or experienced academic failure. On a socio-economic level, we concluded to a rate of 5.8% (lower class), 60.9% (middle class) and 33.3% (upper class). Besides, 40.8% were employed. In total, 23.2% had a psychiatric history. Furthermore, the use of other substances was also prominent and frequent as follows: alcohol 72.5%, tobacco 74.6%, ecstasy 41.3% and 25.4% cocaine. The use of cannabis was considered as a means of indulgence and pleasure for 66.7%, as an anxiolytic for 26.8% and as a sedative for 23.9%. Self-esteem, among those cannabis users, was very low in 20% of cases, low in 38% of cases, medium in 15% of cases and high in 25% of cases.

**Conclusions:** These results lead us to question the relation between cannabis and self-esteem. The question that is evolved about the use of cannabis is the following: Is it used as a remedy or is it the cause of self-esteem deficiency?

**Disclosure:** No significant relationships. **Keywords:** self-esteem; Cannabis; Tunisia

### **EPP0348**

# Modern-type depression and web-based psychopathology in a cohort of Italian university students

L. Orsolini<sup>1</sup>, S. Bellagamba<sup>2</sup>\*, G. Longo<sup>3</sup>, S. Tempia Valenta<sup>4</sup>, V. Salvi<sup>1</sup> and U. Volpe<sup>1</sup>

<sup>1</sup>Unit of Clinical Psychiatric, Polytechnic University of Marche, Ancona, Italy, Department Of Neurosciences/dimsc, Ancona, Italy; <sup>2</sup>Unit of Clinical Psychiatry, Department Of Neurosciences/dimsc, Polytechnic University Of Marche, Ancona, Italy; <sup>3</sup>Polytechnic University of Marche, Department Of Clinical Neurosciences/dimsc, School Of Medicine, Unit Of Psychiatry, Ancona, Italy and <sup>4</sup>Unit of Clinical Psychiatry, Polytechnic University of Marche, Ancona, Italy, Department Of Neurosciences/dimsc, Ancona, Italy

\*Corresponding author.

doi: 10.1192/j.eurpsy.2022.627

**Introduction:** Hikikomori represents the severe social withdrawal condition of the so-called 'modern type-depression' (MTD).

Digital addictions, including Internet addiction (IA), Internet gaming disorder (IGD) and smartphone addiction, have been associated with MTD and Hikikomori.

**Objectives:** This is a post-hoc study aimed at assessing digital addictions in a cohort of university students with a positive screening for MTD and Hikikomori.

**Methods:** A cross-sectional web-based survey was conducted by administering the Hikikomori Questionnaire (HQ-11), Internet Addiction Test (IAT), Internet Gaming Disorder Scale-Short-Form (IGDS9-SF) and the Smartphone addiction scale-Short Version (SAS-SV).

**Results:** Among 1,148 respondents, a significant association was found between the HQ-11 scale and the DASS-21 total score (r=0.434). The HQ-11 positively correlated with IAT, IGDS9-SF and SAS-SV (r=0.329; r=0.292 and r=0.205 respectively).

**Conclusions:** Digital addictions appear to be widely diffuse among university students positive to the Hikikomori and MTD screening. Further longitudinal studies are needed to weight and balance the potential consequences of digital tools in Hikikomori subjects.

**Disclosure:** No significant relationships.

Keywords: digital addiction; Modern Type Depression

#### **EPP0350**

## Growing use of valproic acid in substance use disorders

J. Romão $^{1*}$ , M. Gonçalves $^{1}$ , M. Ribeiro $^{2}$ , R. André $^{1}$ , R. Saraiva $^{1}$  and M. Abreu $^{1}$ 

<sup>1</sup>Centro Hospitalar Universitário Lisboa Norte, Psychiatry, Lisboa, Portugal and <sup>2</sup>Centro Hospitalar Lisboa Norte, Psychiatry, Lisboa, Portugal

\*Corresponding author. doi: 10.1192/j.eurpsy.2022.628

**Introduction:** Valproic acid is an antiepileptic drug used in different fields of Psychiatry. It is known mostly for its use in managing patients with bipolar affective disorder. In psychiatry of addiction, there is still no approved indications for its usage, but it is widely prescribed in treating alcohol and cocaine abuse, due to the existence of studies in these addictions.

**Objectives:** This review aims to clarify the relation between valproic acid and dependences, particularly cocaine.

**Methods:** Non-systematic literature review using a PubMed search, using the following key words: "valproate"; "cocaine use".

Results: Cocaine dependence can decrease GABA levels in humans. Valproic acid has multiple mechanisms that favour the synthesis of GABA, potentiating its release and postsynaptic GABAergic response. Because of this, valproic acid was found effective in promoting abstinence and in reducing the use of cocaine. There are studies that support the valproic acid's use in alcohol and cocaine dependences. Valproic acid has been shown to be promising in relapse prevention. It has also showed efficacy in the management of impulsivity and irritability, what makes it useful in managing patients with borderline personality disorder – patients at higher risk for alcohol or substance use disorders.

**Conclusions:** Cocaine addiction involves different phenomena and may respond to distinct pharmacologic approaches. Although some studies need to be confirmed by larger clinical trials, valproic acid seems a promising agent as one of some potential treatments